EUVIMEDDescubrir EUVIMED
Übersichtsarbeit

Nucleic acid vaccines‐based therapy for triple‐negative breast cancer: A new paradigm in tumor immunotherapy arena

Raed Obaid Saleh, Fatma M Ibrahim, Harikumar Pallathadka, Irwanjot Kaur, Irfan Ahmad, Saad Hayif Jasim Ali, Ahmed Huseen Redhee, Pallavi Ghildiyal, Mohammed Abed Jawad, Salim B Alsaadi

Cell Biochemistry and Function · 2024

DOI: 10.1002/cbf.3992 ↗

At a glance

Übersichtsarbeit in Cell Biochemistry and Function, 2024. Written by Raed Obaid Saleh and 9 co-authors. Institution: Department of Medical Laboratory Techniques, Al-Maarif University College, Al-Anbar, Iraq. Major MEDLINE topics: Triple Negative Breast Neoplasms, Vaccines, DNA. Cited 9 times so far (Crossref); 123 references. Funded by: King Khalid University.

ResumenSubjectsDatos bibliográficosCiteRelated studies

Abstract (original language)

Nucleic acid vaccines (NAVs) have the potential to be economical, safe, and efficacious. Furthermore, just the chosen antigen in the pathogen is the target of the immune responses brought on by NAVs. Triple‐negative breast cancer (TNBC) treatment shows great promise for nucleic acid‐based vaccines, such as DNA (as plasmids) and RNA (as messenger RNA [mRNA]). Moreover, cancer vaccines offer a compelling approach that can elicit targeted and long‐lasting immune responses against tumor antigens. Bacterial plasmids that encode antigens and immunostimulatory molecules serve as the foundation for DNA vaccines. In the 1990s, plasmid DNA encoding the influenza A nucleoprotein triggered a protective and targeted cytotoxic T lymphocyte (CTL) response, marking the first instance of DNA vaccine‐mediated immunity. Similarly, in vitro transcribed mRNA was first successfully used in animals in 1990. At that point, mice were given an injection of the gene encoding the mRNA sequence, and the researchers saw the production of a protein. We begin this review by summarizing our existing knowledge of NAVs. Next, we addressed NAV delivery, emphasizing the need to increase efficacy in TNBC.

Subjects

MeSH terms (MEDLINE)

Triple Negative Breast NeoplasmsVaccines, DNAHumansMiceAnimalsNucleic Acid-Based VaccinesImmunotherapyDNARNA, Messenger

Author keywords

breast cancerimmune celltumorvaccine

Substances

Nucleic Acid-Based VaccinesDNAVaccines, DNARNA, Messenger

Authors and institutions

  • Department of Medical Laboratory Techniques, Al-Maarif University College, Al-Anbar, Iraq.
  • Community Health Nursing, RAK Medical and Health Sciences University, Ras Al Khaimah, UAE.
  • Geriatric Nursing, Mansoura University, Mansoura, Egypt.
  • Manipur International University, Imphal, Manipur, India.
  • Department of Biotechnology and Genetics, Jain (Deemed-to-be) University, Bengaluru, Karnataka, India.
  • Department of Allied Healthcare and Sciences, Vivekananda Global University, Jaipur, Rajasthan, India.

Funding

  • King Khalid University

Cite

APA

Saleh, R. O., Ibrahim, F. M., Pallathadka, H., Kaur, I., Ahmad, I., Ali, S. H. J., Redhee, A. H., Ghildiyal, P., Jawad, M. A., & Alsaadi, S. B. (2024). Nucleic acid vaccines‐based therapy for triple‐negative breast cancer: A new paradigm in tumor immunotherapy arena. Cell Biochemistry and Function. https://doi.org/10.1002/cbf.3992

Vancouver

Saleh RO, Ibrahim FM, Pallathadka H, Kaur I, Ahmad I, Ali SHJ, et al. Nucleic acid vaccines‐based therapy for triple‐negative breast cancer: A new paradigm in tumor immunotherapy arena. Cell Biochemistry and Function. 2024. doi:10.1002/cbf.3992

BibTeX
@article{Saleh2024,
  author = {Saleh, Raed Obaid and Ibrahim, Fatma M and Pallathadka, Harikumar and Kaur, Irwanjot and Ahmad, Irfan and Ali, Saad Hayif Jasim and Redhee, Ahmed Huseen and Ghildiyal, Pallavi and Jawad, Mohammed Abed and Alsaadi, Salim B},
  title = {Nucleic acid vaccines‐based therapy for triple‐negative breast cancer: A new paradigm in tumor immunotherapy arena},
  journal = {Cell Biochemistry and Function},
  year = {2024},
  doi = {10.1002/cbf.3992}
}
Start for free →